An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipifarnib (Primary)
Indications Head and neck cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer; Thyroid cancer
Focus Proof of concept; Therapeutic Use
Acronyms RUN-HN
Sponsors Kura Oncology

12 May 2021 Status changed from active, no longer recruiting to completed.
22 Mar 2021 Results published in the Journal of Clinical Oncology
24 Feb 2021 According to a Kura Oncology media release, Based on data from this trial, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC) with variant allele frequency = 20% after disease progression on platinum-based chemotherapy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com